PET (Positron Emission Tomography) and SPECT (Single Photon Emission Computed Tomography) Global Market (Technology and Applications) (2011-2016)

Report Summary

The global economy is heading towards a double dip phenomenon. The scenario is not very conducive for high-end capital equipments such as PET and SPECT scanners. This is delaying the purchase of new equipments and boosting the market for refurbished instruments.

Increasing awareness among the physicians with respect to nuclear imaging techniques, mounting application areas such as neurological diseases, and rising cases in oncology are driving the PET and SPECT imaging market.

Increasing aging population and widening applications of PET and SPECT imaging due to continuous developments and discovery of new radiopharmaceuticals are predominantly driving the diagnostic imaging market.

The emerging trend catching interest of the players is fusion of nuclear imaging with different modalities of diagnostic imaging products. The merging of imaging modalities such as PET/CT, SPECT/CT, and MRI/PET helps in providing full gamut of imaging scans through the same unit and at the same time. Further, portable diagnostic equipment are facing an immense demand from physicians.

PET is more preferred as compared to SPECT imaging as PET provides higher resolution images, and the lack of availability of technetium-99m for SPECT is forcing the medical community and the industry to look for alternatives. On the other hand, the high cost of PET restricts its use in cost sensitive markets.

PET is predominately used in oncology as the quality of image provided gives more comprehensive information about the tumor. SPECT, on the other hand, holds 90% share in cardiology. PET is catching up with new radiopharmaceuticals, specifically for cardiac PET.

The U.S. accounts for the highest share of the global PET and SPECT market; followed by Europe. Asia-Pacific (excluding Japan) stands third. The growth in the medical device industry has been spurred by Asian economies (China and India) and a few countries of South America (Brazil and Peru). Rest of the world is still lagging behind in nuclear imaging market.

Aging population and increase in the chronic disease population are considered as the main drivers of the PET and SPECT market in the developed nations and rising fiscal deficit and economic recession are expected to inhibit the growth of the developed nations.

The PET and SPECT market is highly consolidated with most of it being held by a few major players. GE Healthcare (U.K.), Philips (The Netherlands), and Siemens (Germany) together constitute above 85% of the market. GE Healthcare is a leading player due to better accompanying services along with the products. The other players trying to make an entry into the niche market are Positron Corporation (U.S), Spectrum (U.S), and Naviscan (U.S).

Scope of the report

Global PET and SPECT imaging market research report evaluates the global market of PET (Positron Emission Tomography) and SPECT (Single Photon Emission Computed Tomography) imaging with respect to the product and application market. The report analyzes geography; forecasting revenue, and trends in each of the following submarkets:

• PET
• PET/CT
• SPECT
• SPECT/CT

PET and SPECT market is also considered by the types of applications:

• Oncology
• Cardiology
• Neurology

The geographies covered under the report are

• North America
• Europe
• Asia-Pacific (excluding Japan)
• Japan
• Rest of the World

Each section provides market data, market drivers, trends and opportunities, key players, and competitive outlook. The report does provide market tables for covering the sub-segments and micro-markets. Additionally, it makes ways for company profiles that cover all the sub-segments. The report has been made by keeping past trends, current happenings and future forecasts in minds.

TABLE OF CONTENTS

EXECUTIVE SUMMARY 

1 INTRODUCTION
1.1 Key take-aways
1.2 Report description
1.3 Markets covered
1.4 Stakeholders
1.5 Research methodology
 
2 SUMMARY

3 MARKET OVERVIEW
3.1 Introduction
3.1.1 Evolution of PET technology
3.1.1.1 Challenges in early stages
3.1.1.2 Concerted efforts to resolve concerns of infrastructure & finance
3.1.1.2.1 Facilities’ to purchase patient-specific doses
3.1.1.2.2 Limited financial risk for hospitals
3.1.2 Learning Curve Of PET
3.2 Emerging therapeutic uses of PET
3.3 Hybrid imaging edges past stand-alone modules
3.4 Non-linear fusion capability – a new opportunity in hybrid imaging
3.4.1 Advantages of non-linear software-based system
3.5 Comparison of U.S. & Europe in PET/CT installations
3.5.1 End User profile – hospitals command maximum PET/CT installations in both geographies
3.6 Decreasing impact of stand alone pet in oncology in U.S.
3.7 Emerging markets for PET
3.8 Low-cost production centers to lower price-tag
3.8.1 GE healthcare focus is on India
3.8.2 Positron corporation’s – production center in China
3.8.3 Siemens healthcare – tapping market potential in emerging countries
3.9 Winning imperatives – different for PET and SPECT
3.10 Market share analysis – GE and Siemens lead the field
3.11 Ancillary products markets of PET
3.11.1 Radionuclides used in PET – FDG most used drug
3.11.2 Scintillation detectors – BGO the most preferred
3.12 Competitive landscape
3.13 Factors influencing market growth
3.13.1 Demand side drivers
3.13.2 Supply side drivers
3.13.3 Threats
3.13.4 Opportunities
3.13.5 Key competitive points
3.14 Patent growth analysis
 
4 PET SPECT MARKET BY TECHNOLOGY
4.1 PET
4.1.1 Drivers
4.1.1.1 PET for cancer management
4.1.1.2 Increasing aging population
4.1.1.3 Enhanced reimbursement scenario for PET in U.S.
4.1.1.4 Ready availability of radiopharmaceuticals from cyclotrons
4.1.2 Prohibition of self-referral is a restraint
4.1.3 Stand alone PET
4.1.3.1 Cardiac operations – opportunity for stand alone PET
4.1.3.2 Restraints
4.1.3.2.1 Dominance of hybrid PET/CT leads to decline in demand for stand-alone PET
4.1.3.2.2 Availability of refurbished hybrid systems dampens demand for new stand-alone PET scanners
4.1.4 PET/CT
4.1.4.1 Drivers and opportunities
4.1.4.1.1 Continuous improvement in PET/CT product Lines support growth in revenue
4.1.4.1.2 PET/CT plays an important role in treatment planning
4.1.4.1.3 Decreased market barriers to entry stimulates PET/CT sales
4.1.4.2 High price tag prohibits sales to end users
4.1.5 PET/MRI
4.1.5.1 Potential clinical applications
4.1.5.2 Superior imaging compared to CT in neurological studies
4.1.5.3 Clinical PET/MRI in Boston – steps by Siemens and Philips
4.2 Difference between PET and SPECT
4.3 SPECT
4.3.1 Stand-alone SPECT
4.3.1.1 Drivers
4.3.1.1.1 SPECT helps from detection to evaluation of treatment of neurological diseases
4.3.1.1.2 Helps in improved treatment for cardio-vascular diseases using SPECT
4.3.1.1.3 Low cost radionuclides help SPECT to gain an edge over PET
4.3.1.2 Low spatial resolution & absence of anatomical data
4.3.2 SPECT/CT
4.3.2.1 Drivers
4.3.2.1.1 Advanced technology increases confidence in SPECT/CT
4.3.2.1.2 Opportunity in niche application drives growth
4.3.2.2 Restraints
4.3.2.3 Availability of novel imaging agents is crucial
4.3.2.4 Technologist training is important
 
5 PET SPECT APPLICATION MARKET
5.1 PET SPECT applications
5.1.1 Oncology
5.1.1.1 Non-small-cell lung cancer
5.1.1.2 Hodgkin and non-hodgkin lymphoma
5.1.1.3 Colorectal cancer
5.1.1.4 Breast cancer
5.1.1.5 Head and neck cancer
5.1.2 Cardiology
5.1.3 Neurology

6 GEOGRAPHIC ANALYSIS
6.1 U.S. PET SPECT market
6.2 EMEA PET SPECT market
6.3 APAC PET SPECT market

7 COMPETITIVE LANDSCAPE
7.1 Competitive scenario
7.2 Competitive structure
7.3 PET commands significantly more competitive development

8 COMPANY PROFILES 
8.1 AGFA-GEVAERT N.V. 
8.1.1 Overview 
8.1.2 Primary business 
8.1.3 Strategy 
8.1.4 Developments 
8.2 ALOKA CO. LTD. 
8.2.1 Overview 
8.2.2 Primary business 
8.2.3 Strategy 
8.2.4 Developments 
8.3 CARDIARC LTD. 
8.3.1 Overview 
8.3.2 Primary business 
8.3.3 Strategy 
8.3.4 Developments 
8.4 COVIDIEN PLC. 
8.4.1 Overview 
8.4.2 Primary business 
8.4.3 Strategy 
8.4.4 Developments 
8.5 DIGIRAD CORPORATION 
8.5.1 Overview 
8.5.2 Primary business 
8.5.3 Strategy 
8.5.4 Developments 
8.6 ESAOTE S.P.A. 
8.6.1 Overview 
8.6.2 Primary business 
8.6.3 Strategy 
8.6.4 Developments 
8.7 GAMMA MEDICA IDEAS INC. 
8.7.1 Overview 
8.7.2 Primary business 
8.7.3 Developments 
8.8 GE HEALTHCARE 
8.8.1 Overview 
8.8.2 Primary business 
8.8.3 Strategy 
8.8.4 Developments 
8.9 HOLOGIC INC. 
8.9.1 Overview 
8.9.2 Primary business 
8.9.3 Strategy 
8.9.4 Developments 
8.10 MEDX, INC. 
8.10.1 Overview 
8.10.2 Primary business 
8.10.3 Strategy 
8.10.4 Developments 
8.11 MERGE HEALTHCARE, INC. 
8.11.1 Overview 
8.11.2 Primary business 
8.11.3 Strategy 
8.11.4 Developments 
8.12 NAVISCAN, INC. 
8.12.1 Overview 
8.12.2 Primary business 
8.12.3 Strategy 
8.12.4 Developments 
8.13 PHILIPS ELECTRONICS 
8.13.1 Overview 
8.13.2 Primary business 
8.13.3 Strategy 
8.13.4 Developments 
8.14 POSITRON CORPORATION 
8.14.1 Overview 
8.14.2 Primary business 
8.14.3 Strategy 
8.14.4 Developments 
8.15 SEGAMI CORPORATION 
8.15.1 Overview 
8.15.2 Primary business 
8.15.3 Strategy 
8.15.4 Developments 
8.16 SIEMENS HEALTHCARE 
8.16.1 Overview 
8.16.2 Primary business 
8.16.3 Strategy 
8.16.4 Developments 
8.17 SPECTRUM DYNAMICS LTD. 
8.17.1 Overview 
8.17.2 Primary business 
8.17.3 Strategy 
8.17.4 Developments 

APPENDIX 
U.S. Patents
EUROPE Patents
JAPAN Patents

LIST OF TABLES 
 
1  Global PET Spect market, by revenues 2008 – 2015 ($Million)
2  Global PET SPECT installations, by products 2008 – 2015 (No. of units) 
3  Type of image fusion
4  Company-wise investment in PET mostly directed to India
5  Winning imperatives for PET and SPECT market
6  Radionuclides used in PET imaging
7  Detector material used in PET imaging
8  Global PET market, by products 2008 – 2015 ($Million)
9  Global PET market, by geography 2008 – 2015 ($Million)
10 Global PET installations, by products 2008 – 2015 (No. of units) 
11 Global PET installations, by geography 2008 – 2015 (No. of units) 
12 Global stand alone PET market, by geography 2008 – 2015 ($Million)
13 Global stand alone PET installations, by geography 2008 – 2015 (No. of units) 
14 Global PET/CT market, by geography 2008 – 2015 ($Million)
15 Global PET/CT installations, by geography 2008 – 2015 (No. of units) 
16 Global SPECT market, by products 2008 – 2015 ($Million)
17 Global SPECT market, by geography 2008 – 2015 ($Million)
18 Global SPECT installations, by products 2008 – 2015 (No. of units) 
19 Global SPECT installations, by geography 2008 – 2015  (No. of units) 
20 Global stand alone SPECT market, by geography 2008 – 2015 ($Million)
21 Global stand alone SPECT installations, by geography 2008 – 2015 (No. of units) 
22 Global SPECT/CT market, by geography 2008 – 2015 ($Million)
23 Global SPECT/CT installations, by geography 2008 – 2015 (No. of units) 
24 Global PET SPECT market, by applications 2008 – 2015 ($Million)
25 Global oncology market, by applications 2008 – 2015 ($Million)
26 Global non-small-cell lung cancer market, by geography 2008 – 2015 ($Million)
27 Global hodgkin and non-hodgkin lymphoma market, by geography  2008 – 2015 ($Million) 
28 Global colorectal cancer market, by geography 2008 – 2015 ($Million)
29 Global breast cancer market, by geography 2008 – 2015 ($Million)
30 Global head and neck cancer market, by geography 2008 – 2015 ($Million) 
31 Global cardiology market, by geography 2008 – 2015 ($Million)
32 Global neurology market, by geography 2008 – 2015 ($Million)
33 Global PET SPECT market, by geography 2008 – 2015 ($Million)
34 Global PET SPECT installations, by geography 2008 – 2015 (No. of units) 
35 U.S. PET SPECT market, by products 2008 – 2015 ($Million)
36 U.S. PET SPECT installations, by products 2008 – 2015 (No. of units) 
37 Emea PET SPECT market, by products 2008 – 2015 ($Million)
38 EMEA PET SPECT installations, by products 2008 – 2015 (No. of units) 
39 APAC PET SPECT market, by products 2008 – 2015 ($Million)
40 APAC PET SPECT installations, by products  2008 – 2015 (No. of units)
41 Mergers and acquisitions (June 2008 – August 2009)
42 Agreements, Collaborations, joint ventures (April 2008 – August 2010)
43 New product launches (January 2008 – March 2010)
44 Services and developments (June 2008 – June 2010)

LIST OF FIGURES 

1  PET application market share in 2009
2  Evolution of PET
3  Emerging therapeutic uses of PET
4  U.S. leads Europe in installations in 2009
5  Hospitals have more PET/CT installed than non-hospitals
6  Pet and PET/CT utilization in oncology in U.S.
7  Relative evaluation of emerging countries in market competitiveness
8  India, favored site for investment since 2008
9  Global PET SPECT market analysis (Units Installed) 2009
10 Global PET market analysis (units installed) 2009
11 Global SPECT market analysis (units installed) 2009
12 Competitive landscape of PET and SPECT market
13 Driving factor analysis of PET SPECT market
14 Patents by assignee (2005 – 2010)
15 Patent analysis, by geography (2005 – 2010)
16 Patents by products (2005 – 2010)
17 YOY patent analysis (2005 – 2010)
18 Potential clinical applications of PET/MRI
19 Difference between PET and SPECT
20 Competitive scenario of leading players in PET and SPECT, 2008 – 2010
21 Strategic developments (January 2008 – June 2010)
22 Comparison of competitive development between PET and SPECT